Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23 – Endpoints News

by

  1. Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23 Endpoints News
  2. Moderna and Merck cancer vaccine used with Keytruda reduces risk of deadly skin cancer spreading CNBC
  3. Cancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data KSL.com
  4. Moderna and Merck reveal new data on individualized cancer treatment MarketWatch
  5. Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Yahoo Finance
  6. View Full Coverage on Google News

Read original article here

Leave a Comment